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Abstract 
 
This study tested the hypothesis that watermelon juice supplementation would improve nitric 
oxide bioavailability and exercise performance.  Eight healthy recreationally-active adult 
males reported to the laboratory on two occasions for initial testing without dietary 
supplementation (control condition).  Thereafter, participants were randomly assigned, in a 
cross-over experimental design, to receive 16 days of supplementation with 300 mL·day-1 of 
a watermelon juice concentrate, which provided ~3.4g L-citrulline·day-1 and an apple juice 
concentrate as a placebo.  Participants reported to the laboratory on days 14 and 16 of 
supplementation to assess the effects of the interventions on blood pressure, plasma [L-
citrulline], plasma [L-arginine], plasma [nitrite], muscle oxygenation and time-to-exhaustion 
during severe-intensity exercise.  Compared to control and placebo, plasma [L-citrulline] (29 
± 4, 22 ± 6 and 101 ± 23 µM), [L-arginine] (74 ± 9, 67 ± 13 and 116 ± 9 µM) and [nitrite] 
(102 ± 29, 106 ± 21 and 201 ± 106 nM) were higher after watermelon juice supplementation 
(P<0.01).  However, systolic blood pressure was higher in the watermelon juice (130 ± 11) 
and placebo (131 ± 9) conditions compared to the control condition (124 ± 8 mmHg; 
P<0.05).  The skeletal muscle oxygenation index during moderate-intensity exercise was 
greater in the watermelon juice condition than the placebo and control conditions (P<0.05), 
but time-to-exhaustion during the severe-intensity exercise test (control: 478 ± 80, placebo: 
539 ± 108, watermelon juice: 550 ± 143 s) was not significantly different between conditions 
(P<0.05).  In conclusion, while watermelon juice supplementation increased baseline plasma 
[nitrite] and improved muscle oxygenation during moderate-intensity exercise, it increased 
resting blood pressure and did not improve time-to-exhaustion during severe-intensity 
exercise.  These findings do not support the use of watermelon juice supplementation as a 
nutritional intervention to lower blood pressure or improve endurance exercise performance 
in healthy adults.  
 
 
 
Key Words: nitric oxide; L-arginine; blood pressure; muscle oxygenation; metabolism; 
fatigue 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
1. Introduction 
 
The free radical gas, nitric oxide (NO), is a multi-functional physiological signalling 
molecule that plays an integral role in skeletal muscle perfusion, metabolism, contractility 
and fatigue resistance [1,2].  The most recognised pathway for nitric oxide generation is the 
oxidation of L-arginine catalysed by the nitric oxide synthase enzymes to yield nitric oxide 
and L-citrulline [3].  However, while oral L-arginine supplementation can increase circulating 
[L-arginine] [4,5], and therefore one of the substrates for nitric oxide synthase, whether oral L-
arginine supplementation increases nitric oxide biomarkers (nitrate and nitrite) and improves 
exercise performance is controversial [4,6-9, see 10 for review].  These conflicting findings 
might be linked, at least in part, to significant pre-systemic [11,12] and systemic [11,13-16] 
breakdown of orally ingested L-arginine.  
 
Although traditionally recognised as a product of the nitric oxide synthase-mediated 
oxidation of L-arginine [3], recent evidence suggests that L-citrulline can be recycled back to 
L-arginine [17] and is more effective than orally ingested L-arginine at increasing systemic 
[18,19] and muscle [20] L-arginine.  It has also been reported that L-citrulline 
supplementation can increase the activity of nitric oxide synthase [20] and increase nitric 
oxide biomarkers [19,21], and there is accumulating evidence to suggest that short term 
supplementation with L-citrulline can improve skeletal muscle oxygenation [22], metabolism 
[23-24], force production [23] and fatigue resistance [22].  Therefore, short-term 
supplementation with L-citrulline might represent an effective dietary intervention to increase 
nitric oxide synthase-derived nitric oxide and to improve skeletal muscle perfusion, 
metabolism and exercise performance. 
 
The name for the amino acid, L-citrulline, is derived from the Latin word for watermelon 
(Citrullus), from which it was first extracted [25,26, see 27 for review].  Although L-citrulline 
is a component of a number of different foods, watermelon juice is a particularly rich source 
of L-citrulline.  It has been reported that watermelon juice contains ~ 2.33 g of L-citrulline per 
L of unpasteurised juice [28].  Consequently, watermelon juice ingestion has been reported to 
increase plasma L-citrulline [29] and L-arginine [29,30], and may also increase nitric oxide 
biomarkers [31].  We recently reported that seven days of supplementation with 6 g L-
citrulline·day-1 tended to, but did not significantly, increase plasma [nitrite] [22], a sensitive 
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marker of nitric oxide synthase activity [32].  It has been suggested that concurrently 
supplementing with L-citrulline and glutathione is more effective at increasing plasma nitric 
oxide markers than L-citrulline alone [33].  Since watermelon is rich in glutathione [34] as 
well as L-citrulline, watermelon juice supplementation might represent a more effective 
dietary intervention to increase nitric oxide production than pure L-citrulline supplementation.  
Moreover, watermelon is rich in many antioxidants in addition to glutathione, including 
lycopene and β-carotene [34-36].  Lycopene and β-carotene may increase nitric oxide 
bioavailability since they have been shown to blunt the scavenging of nitric oxide by 
superoxide [37].  Taken together, these observations suggest that watermelon juice could be a 
nitric oxide precursor, but this has yet to be directly tested in humans.  
 
Supplementation with watermelon juice has been reported to enhance aspects of vascular 
health in hypertensive individuals [38-41], but not in normotensive individuals [42].  It has 
also been reported that watermelon juice ingestion can attenuate muscle soreness after 
completing intense exercise [28].  The effect of watermelon juice consumption on exercise 
performance, on the other hand, is unclear.  The acute ingestion of 500 mL watermelon juice, 
which provided a L-citrulline dose of 1.17 g, did not improve performance during 8 × 30 s 
cycle efforts [28], while the acute ingestion of 710 mL watermelon juice, which provided a L-
citrulline dose of ~ 1 g, did not increase the number of repetitions completed during 5 sets of 
bench press at 80% of the 1 repetition maximum, or increase time-to-exhaustion, the gas 
exchange threshold or maximal oxygen uptake during an incremental treadmill test to 
exhaustion [42].  Since neither of these studies [28,42] assessed plasma [L-citrulline], [L-
arginine] and nitric oxide biomarkers, it is unclear whether these watermelon juice 
interventions were effective at increasing nitric oxide production.  Moreover, both these 
studies only administered a small acute dose of L-citrulline and it has yet to be determined 
whether consuming a larger L-citrulline dose through watermelon juice supplementation can 
improve nitric oxide biomarkers and exercise performance.   
 
The purpose of this study was to assess the effects of chronic supplementation of watermelon 
juice on plasma L-citrulline, plasma L-arginine, plasma nitrite, muscle oxygenation, 
pulmonary oxygen uptake, and exercise performance.  We hypothesised that, compared to a 
placebo condition, concentrated watermelon juice supplementation would increase plasma [L-
citrulline], [L-arginine] and [nitrite] and improve muscle oxygenation, pulmonary O2 
kinetics and exercise performance.   
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2. Methods 
 
2.1 Subjects 
Eight healthy, recreationally-active males (mean ± SD, age 22 ± 2 yr, height 1.83 ± 0.09 m, 
body mass 79 ± 12 kg) volunteered to participate in this study.  None of the subjects were 
tobacco smokers or users of protein supplements or putative nitric oxide donors (L-citrulline, 
L-arginine or nitrate).  The procedures employed in this study were approved by the 
Institutional Research Ethics Committee.  All subjects gave their written informed consent 
prior to the commencement of the study, after the experimental procedures, associated risks, 
and potential benefits of participation had been explained.  Subjects were instructed to arrive 
at the laboratory in a rested and fully hydrated state, at least 3 h postprandial, and to avoid 
strenuous exercise in the 24 h preceding each testing session.  Each subject was also asked to 
refrain from caffeine and alcohol 6 and 24 h before each test, respectively.  All tests were 
performed at the same time of day (± 2 hours). 
 
2.2 Experimental Design 
Subjects were required to report to the laboratory on eight occasions over 7-9 weeks to 
complete the experimental testing (see Figure 1 for a schematic of the experimental design).  
On the first visit to the laboratory, subjects completed a ramp incremental exercise test for 
determination of the gas exchange threshold and the peak oxygen uptake ( O2peak).  Subjects 
were familiarized with the two exercise performance tests employed in this study during the 
second laboratory testing session.  After these preliminary exercise tests, subjects returned to 
the laboratory on two further occasions within 7 days of the final familiarisation trial without 
undergoing any dietary supplementation (the control trials), with these two tests being 
separated by 48 hours recovery.  Thereafter, participants were assigned to receive two 
separate 16-day supplementation periods with either a watermelon juice concentrate or an 
apple juice concentrate as a placebo to complete the experimental testing.  During these 
laboratory visits, blood pressure, muscle oxygenation, pulmonary O2 kinetics and exercise 
performance were assessed, and a resting venous blood sample was obtained.  The 
supplements were administered orally in a counter-balanced order as part of a double blind, 
cross-over experimental design.  Each supplementation period was separated by 7-10 days of 
washout.  Subjects were required to complete a food diary for the control trials.  Specifically, 
they were asked to record food and drink intake for 5 days, starting two days prior to the first 
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control trial and ending on the day of the final control trial.  They were provided with a list of 
foods rich in nitrate and asked to avoid these foods whilst completing the food diary to avoid 
a potential confounding influence of dietary nitrate intake on the physiological and 
performance measurements completed in this study [43]. Subjects were instructed to replicate 
their diet for the final 5 days of the subsequent supplementation periods.  The subjects were 
naive to the experimental hypotheses and were informed that this study sought to investigate 
the effects of supplementation with two fruit juices on exercise performance. 
 
2.3 Incremental Test 
During the first laboratory visit subjects completed a ramp incremental cycle test on an 
electronically-braked cycle ergometer (Lode Excalibur Sport, Groningen, the Netherlands).  
Initially, subjects performed 3 min of baseline cycling at 20 W, after which the work rate was 
increased by 30 W/min until exhaustion.  The subjects cycled at a self-selected pedal rate (70-
90 rpm) and this pedal rate along with saddle and handle bar height and configuration was 
recorded and reproduced in subsequent tests.  Breath-by-breath pulmonary gas-exchange data 
were collected continuously during the incremental tests and averaged over consecutive 10-s 
periods.  The o2peak was taken as the highest 30-s mean value attained prior to the subject’s 
volitional exhaustion in the test.  The gas exchange threshold was determined from a cluster 
of measurements including 1) the first disproportionate increase in CO2 production ( co2) 
from visual inspection of individual plots of co2 vs. O2, 2) an increase in expired 
ventilation ( E) / O2 with no increase in E / co2, and 3) an increase in end-tidal O2 tension 
with no fall in end-tidal CO2 tension.  The work rates that would require 90% of the gas 
exchange threshold (moderate-intensity exercise) and 70% ∆ (gas exchange threshold plus 
70% of the difference between the work rate at the gas exchange threshold and o2peak; 
severe-intensity exercise) were subsequently calculated with account taken of the mean 
response time for O2 during ramp exercise (i.e., two thirds of the ramp rate was deducted 
from the work rate at gas exchange threshold and peak).   
 
 
2.4 Familiarization Tests 
To avoid any order effect on the performance results as a consequence of a potential ‘learning 
effect’, subjects were familiarised with all performance tests prior to the experimental testing.  
Subjects completed a severe-intensity step exercise test terminating with an all-out effort 
(exercise performance test) followed, after a 45 min passive recovery period, by a severe-
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intensity constant-work-rate step exercise test that was continued until exhaustion (time-to-
exhaustion test).   
 
2.5 Supplementation Procedures 
In addition to the unsupplemented control trials, experimental testing was conducted during 
separate 16-day supplementation periods with watermelon juice and placebo (supplied by 
Cobell, Exeter, United Kingdom).  The watermelon juice and placebo juice concentrates 
provided 259 kcal, 1.3 g protein, 61.8 g carbohydrate (as sugar), 0.025 g fat (6.4 mg as 
saturated fatty acids), 0.075 g dietary fibre and 42.2 mg sodium per 100 g of juice.  A sample 
from the batch of watermelon juice used was sent to AltaBioscience (Building Y10, 
University of Birmingham, Birmingham, United Kingdom) for determination of its amino 
acid content via ion exchange chromatography.  The analysis revealed that watermelon juice 
contained 11.4 g L-citrulline and 1.39 g L-arginine per litre of juice.  On days 1-13 and 15 of 
watermelon juice and placebo supplementation (when participants did not complete any 
experimental testing), participants were instructed to mix 150 ml of juice with 500 ml water 
in the morning and late afternoon/evening and to consume slowly over a few hours.  On days 
14 and 16 of watermelon juice and placebo supplementation (when participants underwent 
the experimental testing procedures), participants were instructed to mix 150 ml of juice with 
500 ml water 3 hours and 1 hour before reporting to the laboratory and to ensure all juice had 
been ingested 45 min minutes prior to arriving at the laboratory.  Therefore, participants 
received a daily L-citrulline dose of ~ 3.4 g during the watermelon juice supplementation 
period.   
 
2.6 Experimental Tests 
After reporting to the laboratory, subjects were required to rest in a seated position for 10 min 
in an isolated room. Thereafter, blood pressure and pulse rate of the brachial artery was 
measured using an automated sphygmomanometer (Dinamap Pro, GE Medical Systems, 
Tampa, USA) whilst the subject was seated.  Five measurements were taken and the mean of 
the measurements was calculated.  A venous blood sample was then drawn into a lithium-
heparin tube and centrifuged at 4000 rpm and 4°C for 10 min, within 3 min of collection.  
Plasma was subsequently extracted and immediately frozen at -80°C for later analysis of 
[nitrite] via chemiluminescence [43], and [L-arginine] and [L-citrulline] via high-performance 
liquid chromatography (see below for details).  The resting pulse rate, blood pressure and 
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plasma data are expressed as the mean values collected on the two visits for the control, 
watermelon juice and placebo trials.  
 
Thirty minutes after arriving at the laboratory (75 minutes after the ingestion of the 
supplement), subjects completed a series of cycle exercise tests.  We elected to commence 
exercise testing 75 minutes after supplement consumption as the performance trials would 
then commence ~ 90 minutes after supplement consumption, which published 
pharmacokinetic data has shown coincides with peak plasma [L-arginine] after orally 
ingesting 3 g L-citrulline [19].  The exercise protocol consisted of two ‘step’ exercise tests 
including one moderate-intensity step test followed by one severe-intensity exercise bout.  
Therefore, all subjects performed a total of two bouts of moderate-intensity exercise and two 
bouts of severe-intensity exercise for each experimental condition.   
 
Each transition began with 3 min of baseline cycling at 20 W before an abrupt transition to 
the target work rate.  A passive recovery of 5 min separated the transitions.  The moderate-
intensity steps were each of 4 min duration.  On the first control visit and on day 14 of each 
supplementation trial, subjects cycled at a severe-intensity constant-work-rate (70% ∆) until 
exhaustion (see Figure 1 for a schematic of this experimental protocol).  The time-to-
exhaustion was recorded when the pedal rate fell by > 10 rpm below the required pedal rate.  
On day 16 of the supplementation period, subjects cycled for 6 min at a severe-intensity 
constant-work-rate (70% ∆) followed immediately by a 30 s all-out effort (see Figure 1 for a 
schematic of this experimental protocol).  The resistance on the pedals during the 30 s all-out 
effort was set using the linear mode of the Lode ergometer so that the subject would attain the 
power output calculated to be 50% ∆ if they attained their preferred cadence (linear factor = 
power/preferred cadence2).  Subjects were provided with a 5 s countdown prior to the all-out 
effort and were instructed to attain peak power as quickly as possible and to continue 
exercising maximally for the duration of the all-out effort.  No time feedback was given to 
the subjects at any point during the all-out effort.   
 
 
2.7 Measurements  
During all tests, pulmonary gas exchange and ventilation were measured breath-by-breath 
with subjects wearing a nose clip and breathing through a low-dead-space, low-resistance 
mouthpiece and impeller turbine assembly (Jaeger Triple V).  The inspired and expired gas 
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volume and gas concentration signals were continuously sampled at 100 Hz, the latter using 
paramagnetic (O2) and infrared (CO2) analyzers (Jaeger Oxycon Pro, Hoechberg, Germany) 
via a capillary line connected to the mouthpiece.  The gas analyzers were calibrated before 
each test with gases of known concentration and the turbine volume transducer was calibrated 
with a 3-liter syringe (Hans Rudolph, Kansas City, MO).  The volume and concentration 
signals were time-aligned by accounting for the delay in the capillary gas transit and the 
analyzer rise time relative to the volume signal.  Pulmonary gas exchange and ventilation 
were calculated and displayed breath-by-breath. The pulmonary O2 responses in the two 
moderate-intensity and severe-intensity step tests in control, watermelon juice and placebo 
were averaged to improve the signal-to-noise ratio and the confidence surrounding the 
estimation of the O2 kinetic parameters obtained from the exponential modelling procedures 
[44] (see Data Analysis Procedures below). 
   
During the exercise trials, a blood sample was collected from a fingertip into a capillary tube 
over the 20 s preceding the step transition in work rate, the 20 s preceding the completion of 
240 s of moderate cycling exercise and 360 s severe cycling exercise, and also immediately 
following the all-out effort and immediately after exhaustion during the severe-intensity 
constant-work-rate trial.  These whole blood samples were subsequently analyzed to 
determine blood [lactate] and [glucose] (YSI 2300, Yellow Springs Instruments, Yellow 
Springs, OH, United States) within 30 s of collection. 
 
The oxygenation status of the m. vastus lateralis of the right leg was monitored using a 
commercially available near-infrared spectroscopy system (model NIRO 300, Hamamatsu 
Photonics KK, Hiugashi-ku, Japan).  The system consisted of an emission probe that 
irradiates laser beams and a detection probe.  Four different wavelength laser diodes provided 
the light source (776, 826, 845, and 905 nm) and the light returning from the tissue was 
detected by a photomultiplier tube in the spectrometer.  The intensity of incident and 
transmitted light was recorded continuously at 2 Hz and used to estimate concentration 
changes from the resting baseline for oxygenated, deoxygenated, and total tissue 
hemoglobin/myoglobin.  Therefore, the near-infrared spectroscopy data represent a relative 
change based on the optical density measured in the first datum collected.  It should be noted 
here that the contribution of deoxygenated myoglobin to the near-infrared spectroscopy 
signal is presently unclear, and, as such, the terms [oxyhemoglobin], and [deoxyhemoglobin] 
used in this paper should be considered to refer to the combined concentrations of oxygenated 
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and deoxygenated hemoglobin and myoglobin, respectively.  The tissue oxygenation index 
(TOI) was calculated using the following equation: 
 
Tissue	oxygenation	index	 =

	
	× 100   (Eqn 1) 
 
The leg was initially cleaned and shaved around the belly of the muscle, and the optodes were 
placed in the holder, which was secured to the skin with adhesive at 20 cm above the fibular 
head.  To secure the holder and wires in place, an elastic bandage was wrapped around the 
subject’s leg.  The wrap helped to minimize the possibility that extraneous light could 
influence the signal and also ensured that the optodes did not move during exercise.  Indelible 
pen marks were made around the holder to enable precise reproduction of the placement in 
subsequent tests.  The probe gain was set with the subject at rest in a seated position with the 
leg extended at down stroke on the cycle ergometer before the first exercise bout, and near-
infrared spectroscopy data were collected continuously throughout the exercise protocols.  
The data were subsequently downloaded onto a personal computer, and the resulting text files 
were stored on disk for later analysis. 
 
Plasma [L-arginine] and [L-citrulline] were determined by o-phthaldialdehyde (OPA) 
derivatised, fluorescence-detection HPLC, using methods adapted from Jones and Gilligan 
[45]. The high-performance liquid chromatography apparatus was a Perkin Elmer Flexar LC 
system with Chromera software (Perkin Elmer, MASS, USA). In brief, plasma was de-
proteinised in 1.5N perchloric acid, neutralised in 2N potassium hydrogen carbonate, and 
centrifuged. 100 µL of supernatant, 100 µL of 1.2% benzoic acid, and 1.4 mL H2O were 
added to high-performance liquid chromatography vials. 50 µL of unknowns/standards were 
mixed with 50 µL of an OPA solution containing 2-mercaptoethanol (fluoraldehyde o-
phthaldialdehyde reagent solution, Thermo Scientific, IL, USA), enabling the pre-column 
derivatization of amino acids with a highly fluorescent o-phthaldialdehyde adduct. 25 µL of 
derivatised sample was mixed in mobile phase and eluted at 0.8 ml.min-1 through a 4.6 x 150 
mm, 2.7 µm Brownlee SPP C18 reverse-phase analytical column with 5 mm guard column 
with matching specification. A gradient protocol of aqueous mobile phase A (0.05M 
potassium phosphate buffer, pH 7.2) with organic mobile phase B 
(acetonitrile/methanol/water, 40/40/20) was performed: 0 – 1.5 min, 80% Mobile A; 1.5 – 
18.5, 80 – 65%; 23.5, 50%; 32.5, 40%; 36.5, 30%; 43.5, 0%; 51.5, 80%. Fluorescence was 
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monitored at excitation and emission wavelengths of 340 and 455 nm, respectively. Amino 
acid concentrations were determined against standard curves between 0 and 500 µM. 
 
2.8 Data Analysis Procedures 
The breath-by-breath O2 data from each test were initially examined to exclude errant 
breaths caused by coughing, swallowing, sighing, etc., and those values lying more than four 
standard deviations from the local mean were removed.  The breath-by-breath data were 
subsequently linearly interpolated to provide second-by-second values and, for each 
individual, the two moderate-intensity and two severe-intensity repetitions were time-aligned 
to the start of exercise and ensemble-averaged.  For moderate-intensity exercise, baseline and 
end-exercise O2 were taken as the mean O2 over the 90 s preceding the step transition and 
the mean O2 over the final 60 s of the step transition, respectively.  For severe-intensity 
exercise, the first 20 s of data after the onset of exercise (i.e., the phase I response) were 
deleted and a nonlinear least-square algorithm was used to fit the data thereafter.  A bi-
exponential model was used to characterize the O2 responses to severe-intensity exercise, as 
described in the following equation:  
          
O2 (t) = O2 baseline + Ap(1-e- (t-TDp/τp)) + As(1-e- (t-TDs/τs))  (Eqn. 2) 
 
where O2 (t) represents the absolute O2 at a given time t; O2baseline represents the mean O2 
in the baseline period; Ap, TDp, and p represent the amplitude, time delay, and time constant, 
respectively, describing the phase II increase in O2 above baseline; and As, TDs, and s 
represent the amplitude of, time delay before the onset of, and time constant describing the 
development of, the O2 slow component, respectively.   
 
In addition, a single-exponential model without time delay, with the fitting window 
commencing at t = 0 s (equivalent to the mean response time), was used to characterize the 
kinetics of the overall O2 response during the trials as described in the following equation:  
 
O2 (t) = O2 baseline + A (1-e- t/MRT))    (Eqn. 3) 
 
An iterative process was used to minimize the sum of the squared errors between the fitted 
function and the observed values.  O2baseline was defined as the mean O2 measured over the 
final 90 s of the resting baseline period.  The O2 at 360 s was taken as the mean O2 between 
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330 and 360 s, the O2 at exhaustion was taken as the mean O2 measured over the final 30 s 
of the exhaustive exercise bout, and the O2 at the end of the all-out effort was taken as the 
mean O2 measured over the final 15 s of the all-out effort.  Because the asymptotic value 
(As) of the exponential term describing the O2 slow component may represent a higher value 
than is actually reached at the end of the exercise, the actual amplitude of the O2 slow 
component at the end of exercise was defined as As'.  The As' parameter was compared at the 
same iso-time (360-s) for all dietary interventions.  The near-infrared spectroscopy-derived 
TOI was assessed at baseline (90-s mean preceding step transition) and end-exercise (mean 
response over the final 30 s of exercise).   
 
2.9 Statistics 
A one-way repeated-measures ANOVA was employed to assess between-supplement 
differences in blood pressure and heart rate; blood [glucose] and [lactate]; plasma [L-arginine], 
[L-citrulline] and [nitrite]; pulmonary O2; near-infrared spectroscopy-derived tissue 
oxygenation index; and exercise performance indices.  Significant effects were further 
explored using simple contrasts with Fisher’s LSD.  Data are presented as mean ± SD, unless 
otherwise stated.  Statistical significance was accepted when P<0.05.  Effect size was 
calculated as Cohen’s d.    
 
 
3. Results 
 
On the days of the experimental testing, all participants reported mild gastrointestinal (GI) 
discomfort with symptoms of mild stomach cramps and/or flatulence with both the 
watermelon juice and placebo supplements.   All participants consumed at least 95% of the 
required supplement portions and their diet was consistent in the days surrounding each of the 
intervention periods.  In the ramp incremental test, participants attained a peak power output 
of 360 ± 61 W and a o2peak of 4.11 ± 0.71 L·min-1 (52 ± 8 ml·kg-1·min-1).  The work rates 
applied during the moderate-intensity and severe-intensity step tests were 112 ± 22 W and 
274 ± 54 W, respectively.  
 
Plasma [L-citrulline], [L-arginine], and [NO2-]  
The plasma [L-citrulline], [L-arginine], and [NO2-] in the CON, WMJ and PLA conditions are 
illustrated in Figure 2.  There was a significant main effect for supplement on plasma [L-
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citrulline], [L-arginine], and [nitrite].  Plasma [L-citrulline] was higher in the watermelon juice 
condition (101 ± 23 µM) compared to the placebo (22 ± 6 µM) and control (29 ± 4 µM) 
conditions (P<0.001), with plasma [L-citrulline] being lower with PLA than CON (P<0.05; 
Figure 2).  Plasma [L-arginine] was higher in the watermelon juice condition (116 ± 9 µM) 
compared to the placebo (67 ± 13 µM) and control (74 ± 9 µM) conditions (P<0.001), with 
no significant differences between plasma [L-arginine] in the placebo and control trials 
(P>0.05; Figure 2).  Similarly, plasma [nitrite] was higher in the watermelon juice condition 
(201 ± 106 nM) compared to the placebo (106 ± 21 nM) and control (102 ± 29 nM) 
conditions (P<0.05), with no significant differences in plasma [nitrite] between the placebo 
and control trials (P>0.05; Figure 2).  
 
Blood pressure and heart rate 
There was a significant main effect for supplement on heart rate, systolic blood pressure and 
mean arterial pressure (all P<0.05), but not diastolic blood pressure (P>0.05). Heart rate, 
systolic blood pressure and mean arterial pressure were higher in both watermelon juice and 
placebo compared to the control condition (P<0.05; Table 1).  These variables were not 
different between the watermelon juice and placebo conditions (P>0.05; Table 1).  
 
Tissue oxygenation index 
The tissue oxygenation index in the control, watermelon juice and placebo conditions during 
moderate-intensity and severe-intensity cycling exercise is illustrated in Figure 3.  There was 
a significant main effect for supplement on the change (∆ end-start) in tissue oxygenation 
index during moderate-intensity exercise (P<0.05).  Further analysis revealed that tissue 
oxygenation declined by a smaller magnitude during moderate-intensity exercise in the 
watermelon juice condition compared to the placebo and control conditions (P<0.05; Figure 
3).  There were no between-condition differences in tissue oxygenation index during baseline 
cycling (P>0.05), but the tissue oxygenation index at end-exercise was higher in the 
watermelon juice condition that the placebo condition (P<0.05; Figure 3).    There were no 
significant differences between the experimental conditions in tissue oxygenation index at 
baseline or end-exercise during the severe-intensity exercise test (P>0.05; Figure 3). 
 
Pulmonary O2 
There were no significant differences in pulmonary O2 at baseline or end-exercise during the 
moderate-intensity step exercise tests between the three experimental conditions (P>0.05; 
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Table 2).  Likewise, there were no differences in pulmonary O2 at baseline, 360 s, the end of 
the all-out effort or exhaustion during the severe-intensity step exercise tests between the 
three experimental conditions (P>0.05; Table 2).  Moreover, phase II O2 kinetics and the 
O2 fundamental and slow component amplitudes were not significantly different between the 
three experimental conditions (P>0.05; Table 2).  
  
Blood [glucose] and [lactate]  
There were no significant between-condition differences in blood [glucose] at any point of 
the moderate-intensity and severe-intensity step exercise tests.  In contrast, there were 
significant main effects for condition on baseline and end-exercise blood [lactate] during the 
moderate-intensity step tests (P<0.05).  The baseline blood [lactate] during the moderate-
intensity step test was higher with both watermelon juice and placebo supplementation 
compared to the control condition (P<0.05), while end-exercise blood [lactate] was higher 
than the control condition after placebo supplementation (P<0.05; Table 3).  The ANOVA 
indicated a significant main effect for condition on baseline blood [lactate] during the severe-
intensity step test (P<0.05), with baseline blood [lactate] being higher than the control 
condition after watermelon juice and placebo supplementation (P<0.05; Table 3).  There was 
no significant main effect for condition on blood [lactate] at any other time point during the 
severe-intensity exercise test (P>0.05; Table 3). 
 
Exercise performance 
The power output during the 30 s all-out effort in the control, watermelon juice and placebo 
conditions is illustrated in Figure 4.  There was no significant main effect for condition on 
either the peak power output or total work done in the 30 s all-out effort (P>0.05).  However, 
there was a significant main effect for condition on the total work done over the first 10 s of 
the all-out effort (P<0.05; Figure 4).  Follow-up analyses indicated that the total work done 
over the first 10 s of the all-out effort was higher in the watermelon juice condition (4.7 ± 1.7 
kJ) compared to the control condition (4.2 ± 1.4 kJ; P<0.05; Table 4; Figure 4), but not the 
placebo condition (4.5 ± 1.6 kJ; P>0.05).  There was no significant main effect for condition 
on the time to exhaustion during the severe-intensity constant work rate exercise test 
(P>0.05; Table 4).   
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4. Discussion 
 
The important novel finding from this study is that chronic supplementation with a 
watermelon juice concentrate, which provided a daily L-citrulline dose of ~ 3.4 g and 
increased plasma [L-citrulline] and [L-arginine], also increased the sensitive biomarker of 
nitric oxide synthase activity, plasma [nitrite].  In addition, muscle oxygenation during 
moderate-intensity exercise was increased after watermelon juice supplementation.  
However, in spite of a significant increase in plasma [nitrite], watermelon juice increased 
resting blood pressure and heart rate above values observed in the unsupplemented control 
condition.   Muscle oxygenation and performance during severe-intensity exercise, and 
pulmonary O2 during moderate-intensity and severe-intensity exercise were not significantly 
impacted by watermelon juice supplementation.  Therefore, the results of this study suggest 
that, while chronic watermelon juice supplementation has the potential to increase nitric 
oxide synthesis, this benefit is somewhat offset by an increase in resting blood pressure and 
heart rate.  Moreover, given that severe-intensity exercise performance was not improved 
following watermelon juice supplementation, our findings do not support the use of 
watermelon juice as a nutritional aid to improve endurance exercise performance in 
recreationally-active participants. 
 
It is well documented that watermelon juice is rich in L-citrulline [28,30,34,46,47] and that 
orally ingested L-citrulline readily passes into the systemic circulation [48].  Consistent with 
this, 16 days supplementation with 300 mL·day-1 of a watermelon juice concentrate, which 
provided ~ 3.4 g L-citrulline·day-1, increased plasma [L-citrulline] 3-4 fold above values 
observed in the placebo condition.  The two previous studies that have measured plasma [L-
citrulline] following watermelon juice ingestion have reported conflicting findings. 
Specifically, Mandel et al. [29] observed a 26 fold increase in plasma [L-citrulline] after the 
acute consumption of 3.3 kg (wet weight) watermelon (L-citrulline content not quantified), 
whereas plasma [L-citrulline] was not increased after consuming 780 g (~ 1 g L-citrulline) or 
1560 g (~ 2 g L-citrulline) of watermelon juice·day-1 for 3 weeks in the study by Collins et al. 
[30].  These inter-study differences might be linked to differences in the watermelon 
supplementation procedures employed and the L-citrulline doses administered.  However, 
while the effect of watermelon consumption on plasma [L-citrulline] is equivocal, plasma [L-
arginine] was increased in the current study (+42%), as well as the studies by Mandel et al. 
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[29] (+2 fold) and Collins et al. [30] (+10% with the lower dose; +25% with the higher dose) 
compared to the respective placebo/control conditions.  Following oral ingestion, circulating 
L-citrulline is taken up by a number of tissues and subsequently converted, via the stepwise 
activity of the enzymes, arginoinosuccinate synthase and arginoinosuccinate lyase, to L-
arginine [17,49,50].  Therefore, the findings of this study suggest that chronic watermelon 
juice supplementation can increase the circulating L-arginine pool and, by extension, substrate 
for nitric oxide synthase. 
 
In addition to increasing substrate provision for nitric oxide synthase, we observed an 
increase in the circulating plasma [nitrite] after watermelon juice supplementation.  There is 
evidence to suggest that the plasma [nitrite] sensitively reflects endothelial nitric oxide 
synthase activity [32] and that L-citrulline supplementation can increase nitric oxide synthase 
activation [20] and nitric oxide biomarkers [19,21].  The greater plasma [nitrite] after 
watermelon juice supplementation in this study therefore suggests that watermelon juice 
supplementation was effective at increasing nitric oxide synthase-derived nitric oxide.  A 
previous study has reported that nitric oxide synthase activity and plasma [NOx] ([nitrate] + 
[nitrite]) were increased after 4 weeks supplementation with watermelon pomace in Zucker 
diabetic fatty rats [31], but the current study is the first, to our knowledge, to suggest that 
watermelon juice supplementation can increase nitric oxide production through nitric oxide 
synthase in humans.  In a recent study, we reported that seven days supplementation with 6 g 
L-citrulline·day-1 (total L-citrulline dose of 42 g) did not significantly increase plasma 
[nitrite], but the 21% increase did approach statistical significance [22].  However, when a 
similar total L-citrulline dose was administered as concentrated watermelon juice in this 
study, plasma [nitrite] was increased by 90% in spite of a lower increase in plasma [L-
arginine] (+42%) compared to our previous study (+137%) [22].  The greater potential for 
nitric oxide synthesis after watermelon juice supplementation might be linked to a synergistic 
effect between L-citrulline and other constituents of watermelon juice.  For example, 
watermelon juice is high in the non-enzyme antioxidants, glutathione, lycopene and β-
carotene [34-36], which can scavenge the superoxide radical [37,51].  This is important given 
the rapid reaction of superoxide with nitric oxide to form peroxynitrite which compromises 
nitric oxide bioavailability [52].  Importantly, watermelon juice supplementation has been 
shown to increase plasma [lycopene] and [β-carotene] [35] and recent evidence suggests that 
concurrent supplementation with L-citrulline and glutathione is more effective at increasing 
nitric oxide biomarkers than independent supplementation with L-citrulline [33].  Taken 
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together, these findings suggest that watermelon juice supplementation might represent an 
effective nutritional intervention to increase nitric oxide production and bioavailability.      
 
Pulmonary O2 during moderate-intensity exercise was not significantly impacted by 
watermelon juice supplementation in this study.  It has recently been reported that increasing 
the circulating plasma [nitrite] via nitrate-rich beetroot juice supplementation can lower O2 
during moderate-intensity exercise [e.g., 43].  However, plasma [nitrite] was only increased 
by 90% after watermelon juice supplementation in this study and a reduction in O2 during 
moderate-intensity exercise is only typically observed after nitrate-rich beetroot juice 
supplementation when plasma [nitrite] is increased at least 2 fold above baseline when using 
the same plasma [nitrite] assay (ozone-based chemiluminescence analysis of non-
deproteinised plasma) used in this study [43].  Therefore, the increase in nitric oxide 
synthesis after watermelon juice supplementation in this study was likely insufficient to 
evoke an improvement in cycling economy.  However, while the O2 cost of moderate-
intensity exercise was not altered after watermelon juice supplementation, muscle 
oxygenation during moderate-intensity was greater following watermelon juice 
supplementation.  Indices of muscle oxygenation were also improved in our recent study after 
L-citrulline supplementation [22].  Taken together, these findings suggest that 
supplementation with watermelon juice or L-citrulline may improve the balance between 
muscle O2 supply and muscle O2 demand during moderate-intensity exercise.        
 
In contrast to our recent study with L-citrulline supplementation [22], time-to-exhaustion and 
the total work completed during the all-out effort were not improved after watermelon juice 
supplementation compared to placebo in this study.  Two other recent studies have also 
observed no improvement in exercise performance indices after watermelon juice 
supplementation [28,42].  In our previous study where L-citrulline was ergogenic, we 
observed improved muscle oxygenation and faster O2 kinetics and attributed the ergogenic 
effects of L-citrulline to an increase in proportional energy contribution from oxidative 
metabolism [22].  Previous studies have also reported improved muscle function after L-
citrulline supplementation when oxidative metabolism is improved [23,24].  However, 
pulmonary O2 kinetics and muscle oxygenation during severe-intensity exercise were not 
improved by watermelon juice supplementation in this study and exercise performance was 
unaltered.  Collectively, these observations suggest that increasing dietary L-citrulline intake 
has the potential to improve endurance exercise performance only when indices of aerobic 
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metabolism are improved. The improvements in muscle force production/fatigue resistance 
after studies administering L-citrulline powder [22,23] compared to the lack of improvements 
in muscle performance after watermelon juice [28,42, the current study] might be linked to 
the greater L-citrulline doses administered in the studies administering L-citrulline powder.  
To our knowledge, this study has assessed exercise performance variables after the largest L-
citrulline dose administered via watermelon juice.  Given that exercise performance was not 
enhanced with a watermelon juice concentrate in this study, our findings suggest that 
watermelon juice supplementation is unlikely to represent an ergogenic aid for endurance 
performance.  We observed that watermelon juice supplementation and the apple juice 
placebo tended to increase time-to-exhaustion compared to the control condition.  This might 
be linked to the chronic carbohydrate consumption in both the juice concentrate conditions 
compared to the control conditions [53].  There is also evidence that chronic carbohydrate 
consumption does not improve performance during short-duration high-intensity exercise 
[see 54 for review] and the general consensus is that carbohydrate supplementation is not 
necessary to optimise performance during events < 30 min in duration [55].      
 
While watermelon juice supplementation offers promise as a nutritional intervention to 
increase nitric oxide bioavailability and muscle oxygenation during moderate-intensity 
exercise, there were some negative side effects associated with the watermelon juice 
supplementation regime used in this study.  Firstly, participants reported mild gastrointestinal 
discomfort after watermelon juice supplementation that was manifest as mild stomach cramps 
and/or flatulence.  Since similar side effects were reported with placebo supplementation, and 
since previous studies administering a similar L-citrulline dose to that ingested in this study 
have reported no side effects [e.g., 19], the gastrointestinal discomfort after watermelon juice 
supplementation in this study is unlikely to be a consequence of L-citrulline ingestion per se.  
Gastrointestinal discomfort can be provoked by high fat, fibre or protein consumption, or the 
ingestion of a concentrated carbohydrate solution [56].  The watermelon juice and placebo 
supplements were low in fat (0.025 g/100 g juice), fibre (0.075 g/100 g juice) and protein (1.3 
g/100 g juice), but high in carbohydrate (61.8 g sugar/100 g juice).  As such, the 
gastrointestinal discomfort reported after watermelon juice and placebo ingestion is likely to 
have arisen as a consequence of the high sugar content of the watermelon juice and placebo 
supplements.  Secondly, blood pressure and heart rate were increased after watermelon juice 
supplementation.  This conflicts with recent observations that supplementation with 
watermelon juice can lower blood pressure in hypertensive participants [38-41].  Blood 
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pressure and heart rate were increased above the unsupplemented control condition by a 
similar magnitude after watermelon juice and placebo supplementation.  This suggests that 
the high sugar intake with the watermelon juice and placebo supplements might also have 
played a role in increasing blood pressure and heart rate.  Previous studies have also observed 
an increase in blood pressure after the consumption of beverages rich in sugar [e.g., 57].  
Although the mechanism for the increase in blood pressure following the consumption of 
sugar-enriched beverages is not entirely clear, there is some evidence that increased sugar 
intake can increase sympathetic nervous system activity [58].  Therefore, the increased blood 
pressure after watermelon juice and placebo supplementation in this study might be linked to 
an increase in sympathetic drive.  The increase in resting heart rate after watermelon juice 
and placebo supplementation in this study is consistent with this interpretation.  Given the 
increased stress placed on the cardiovascular system after watermelon juice consumption in 
this study, and the increase in coronary heart disease and hypertension morbidity associated 
with the consumption of sugar-sweetened beverages [59], longer term supplementation with a 
watermelon juice concentrate, at least in the form administered in this study, cannot be 
recommended.     
 
Although the watermelon juice concentrate administered in this study was not ergogenic for 
endurance exercise performance and evoked negative cardiovascular responses, it is known 
that the L-citrulline content of watermelon varies by the watermelon variety [46] and that the 
rind of a watermelon contains more L-citrulline than the flesh of the fruit [46,47].  Therefore, 
we acknowledge that it might have been possible to consume a lower volume of watermelon 
juice (with a corresponding reduction in sugar intake) to attain the same or a larger L-
citrulline dose to that administered in the current study if a different watermelon variety had 
been used or more of the rind was incorporated into the watermelon juice.  Administering a 
sugar-free/reduced sugar watermelon juice concentrate might also hold promise given that 
watermelon juice appears to be more effective at increasing nitric oxide production (the 
current study) compare to an equivalent total dose of pure L-citrulline [22].  Further research 
is required to assess the effects of a sugar-free/reduced sugar watermelon juice concentrate 
and lower doses of watermelon juice on nitric oxide production, vascular and metabolic 
function, and functional capacity in healthy adults, as well as patients with vascular and 
metabolic diseases.    
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
5. Conclusion 
In conclusion, 14-16 days supplementation with a watermelon juice concentrate, that 
provided 3.4 g L-citrulline·day-1, increased plasma [nitrite].  This suggests increased nitric 
oxide production through nitric oxide synthase.  During moderate-intensity exercise 
pulmonary O2 was not different but muscle oxygenation was greater after watermelon juice 
supplementation.  This implies that watermelon juice supplementation improved the balance 
between muscle O2 supply and muscle O2 demand during moderate-intensity exercise.  
However, watermelon juice supplementation did not improve pulmonary O2 kinetics, 
muscle oxygenation or exercise performance indices during severe-intensity cycling exercise.  
Moreover, participants experienced gastrointestinal discomfort and exhibited increases in 
resting blood pressure and heart rate after the watermelon juice supplementation regime 
employed in this study.  Therefore, while the results of this study suggest that 
supplementation with a watermelon juice concentrate can elicit improvements in baseline 
nitric oxide production and muscle oxygenation during moderate-intensity exercise, severe-
intensity exercise performance was unaffected, and resting blood pressure and heart rate were 
increased after watermelon juice supplementation compared to placebo supplementation.  
These findings do not support the use of watermelon juice supplementation to aid endurance 
exercise performance and vascular health in healthy adults.       
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Figure Legends 
 
Figure 1: Schematic of the experimental protocol (panel A) and the time to exhaustion (panel 
B) and all-out effort (panel C) tests that were completed in the control condition and during 
16 day supplementation periods with watermelon juice concentrate and apple juice 
concentrate as a placebo. Tlim = time to exhaustion. Note that the watermelon juice and apple 
juice supplements were administered in a counterbalanced order in a crossover experimental 
design.    
 
Figure 2: Plasma [L-citrulline] (upper panel), [L-arginine] (middle panel) and [nitrite] (lower 
panel) in the control (CON) condition and during a 16 day supplementation period with 
watermelon juice concentrate (WMJ) and apple juice concentrate as a placebo (PLA).  The 
open bars represent the group mean ± SD responses in the CON, WMJ and PLA conditions.  
The solid black lines represent the individual responses to the supplements. * indicates 
significantly different from CON and PLA (P<0.05). # indicates significantly different from 
CON (P<0.05).   
 
Figure 3: Group mean near-infrared spectroscopy-derived tissue oxygenation index during a 
moderate-intensity step cycle test (upper panel) and a severe-intensity step cycle test (lower 
panel)  in the control (CON) condition and during a 16 day supplementation period with 
watermelon juice concentrate (WMJ) and apple juice concentrate as a placebo (PLA).  Note 
the improved tissue oxygenation index with WMJ during moderate-intensity cycling exercise.  
 
Figure 4: Group mean power profiles during a 30 s all-out effort commenced immediately 
after 6 min of severe-intensity cycle exercise in the control (CON) condition and during a 16 
day supplementation period with watermelon juice concentrate (WMJ) and apple juice 
concentrate as a placebo (PLA).  The dashed vertical line represents the onset of the 30-s all-
out effort. * indicates a significantly higher mean power output over the first 10-s of the all-
out effort in the WMJ condition compared to the CON condition.   
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Table 1. Resting blood pressure and heart rate measures during the control (CON), 
watermelon juice (WMJ) and placebo (PLA) conditions. 
 
 CON WMJ PLA CON-WMJ PLA-WMJ 
 
   Mean 
Difference 
(95% CI) 
Effect 
Size 
Mean 
Difference 
(95% CI) 
Effect 
Size 
Heart rate (bpm) 66 ± 4 76 ± 6* 77 ± 8* -9.88 (-
16.12, -
3.63) 
1.32 0.50 (-
7.68, 8.68) 
0.05 
Systolic blood pressure (mmHg) 124 ± 8 130 ± 11* 131 ± 9* -6.13 (-
11.38, -
0.87) 
0.98 1.13 (-
2.57,4.82) 
0.26 
Diastolic blood pressure (mmHg) 68 ± 4 69 ± 9* 68 ± 7* -1.63 (-
6.00, 2.75) 
0.31 -1.00 (-
8.21, 6.21) 
0.12 
Mean arterial pressure (mmHg) 89 ± 5 92 ± 7* 92 ± 7* -2.75 (-
5.15, -
0.35) 
0.96 0.13 (-
2.95, 3.20) 
0.04 
Values are presented as the mean ± SD. * = significantly different from CON (P<0.05). 95% 
CI = 95% confidence interval. 
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Table 2. Pulmonary oxygen uptake ( O2) during moderate- and severe-intensity cycle 
exercise in the control (CON), watermelon juice (WMJ) and placebo (PLA) conditions. 
 
 CON WMJ PLA CON-WMJ PLA-WMJ 
 
   Mean 
Difference 
(95% CI) 
Effect 
Size 
Mean 
Difference 
(95% CI) 
Effect 
Size 
Pulmonary O2         
Moderate-intensity cycling        
Baseline (L·min-1) 1.10 ± 0.18 1.10 ± 0.17 1.08 ± 0.15 -0.01 (-
0.07, 0.47) 
0.14 -0.02 (-
0.10, 0.64) 
0.2 
End-exercise (L·min-1) 1.84 ± 0.40 1.91 ± 0.31 1.91 ± 0.29 -0.07 (-
0.26, 0.11) 
0.32 -0.02 (-
0.08, 0.05) 
0.25 
        
Severe-intensity cycling        
Baseline (L·min-1) 1.13 ± 0.18 1.17 ± 0.16 1.17 ± 0.12 -0.04 (-
0.07, 0.00) 
0.75 -0.00 (-
0.08, 0.08) 
0.01 
360-s (L·min-1) 3.88 ± 0.63 3.84 ± 0.64 3.95 ± 0.63 0.03 (-
0.02, 0.09) 
0.50 0.11 (-
0.05, 0.27) 
0.58 
Phase II time Constant (s) 28 ± 6 26 ± 3 29 ± 4 2.08 (-
3.47, 7.62) 
0.31 2.79 (-
2.38, 7.95) 
0.45 
Fundamental amplitude 
(L·min-1) 
2.16 ± 0.52 2.11 ± 0.54 2.23 ± 0.52 0.05 (-
0.08, 0.19) 
0.31 0.11 (-
0.02, 0.25) 
0.69 
Slow component amplitude 
(L·min-1) 
0.61 ± 0.14 0.60 ± 0.17 0.60 ± 0.16 0.01 (-
0.09, 0.10) 
0.08 0.00 (-
0.08, 0.08) 
0.00 
Overall mean response time 
(s) 
57 ± 12 58 ± 9 57 ± 11 -0.10 (-
4.66, 4.46) 
0.02 -0.23 (-
4.91, 4.47) 
0.04 
End-sprint (L·min-1) 4.12 ± 0.74 4.08 ± 0.57 4.14 ± 0.76 0.04 (-
0.20, 0.28) 
0.14 0.06 (-
0.17, 0.29) 
0.22 
Exhaustion (L·min-1) 3.99 ± 0.48 3.91 ± 0.66 4.04 ± 0.59 0.08 (-
0.12, 0.29) 
0.32 0.13 (-
0.12, 0.39) 
0.42 
Values are presented as the mean ± SD. 95% CI = 95% confidence interval. 
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Table 3. Blood [glucose] and [lactate] during moderate- and severe-intensity cycle 
exercise in the control (CON), watermelon juice (WMJ) and placebo (PLA) conditions. 
 
 CON WMJ PLA CON-WMJ PLA-WMJ 
 
   Mean 
Difference 
(95% CI) 
Effect 
Size 
Mean 
Difference 
(95% CI) 
Effect 
Size 
Blood glucose concentration 
(mM) 
       
Moderate-intensity cycling        
Baseline 4.0 ± 0.8 4.1 ± 0.7 4.1 ± 0.6 -0.13 (-
1.08, 
0.82) 
0.11 -0.02 (-
0.74, 
0.70) 
0.02 
End-exercise 4.2 ± 0.4 3.8 ± 0.9 4.1 ± 0.8 0.43 (-
0.34, 
1.20) 
0.47 0.25 (-
0.52, 
1.01) 
0.27 
        
Severe-intensity cycling        
Baseline 4.0 ± 0.8 4.1 ± 0.6 4.3 ± 0.5 -0.88 (-
1.16, 
0.99) 
0.68 0.23 (-
0.50, 
0.95) 
0.26 
360-s 3.9 ± 0.4 4.2 ± 0.5 4.1 ± 1.0 0.23 (-
0.44, -
0.01) 
0.89 -0.38 (-
0.71, 
0.64) 
0.47 
Post 30-s sprint 4.0 ± 0.7 4.0 ± 0.5 4.3 ± 0.6 -0.01 (-
0.63, 
0.61) 
0.01 0.30 (-
0.17, 
0.77) 
0.54 
Post exhaustion 3.4 ± 0.9 3.8 ± 0.7 4.1 ± 1.0 -0.39 (-
1.11, 
0.33) 
0.45 0.31 (-
0.40, 
1.03) 
0.36 
        
Blood lactate concentration 
(mM) 
       
Moderate-intensity cycling        
Baseline 0.9 ± 0.3 1.5 ± 0.3* 1.4 ± 0.3* -0.61 (-
0.80, -
0.41) 
2.65 -0.11 (-
0.27, 
0.05) 
0.58 
End-exercise 1.3 ± 0.6 1.6 ± 0.5 1.6 ± 0.5* -0.26 (-
0.60, 
0.08) 
0.63 0.07 (-
0.15, 
0.28) 
0.28 
        
Severe-intensity cycling        
Baseline 0.9 ± 0.3 1.3 ± 0.4* 1.3 ± 0.3* -0.40 (-
0.79, -
0.01) 
0.87 0.03 (-
0.23, 
0.28) 
0.10 
360-s 6.9 ± 1.7 7.5 ± 2.1 7.4 ± 2.0 -0.59 (-
1.87, -
0.70) 
0.38 -0.08 (-
1.44, 
1.29) 
0.05 
Post 30-s sprint 9.3 ± 1.6 9.6 ± 1.5 10.1 ± 2.2 -0.29 (- 0.79 0.51 (- 0.31 
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1.24, 
0.66) 
0.88, 
1.91) 
Post exhaustion 7.3 ± 2.0 8.4 ± 2.5 8.7 ± 2.0 -1.07 (-
2.99, 
0.86) 
0.46 0.34 (-
1.30, 
1.98) 
0.17 
Values are presented as the mean ± SD. * = significantly different from CON (P<0.05). 95% 
CI = 95% confidence interval. 
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Table 4. Exercise performance measures in the control (CON), watermelon juice 
(WMJ) and placebo (PLA) conditions. 
 
 CON WMJ PLA CON-WMJ PLA-WMJ 
 
   Mean 
Difference 
(95% CI) 
Effect 
Size 
Mean 
Difference 
(95% CI) 
Effect 
Size 
Sprint test performance        
Peak power output (W) 509 ± 167 565 ± 200 547 ± 196 -56.75 (-
102.84, -
10.66) 
1.03 -18.38 (-
75.05, 
38.30) 
0.27 
Total work done over 10 s (kJ) 4.2 ± 1.4 4.7 ± 1.7* 4.5 ± 1.6 -0.54 (-
0.93, -
0.16) 
1.17 -0.19 (-
0.60, 0.21) 
0.39 
Total work done over 30 s (kJ) 12.5 ± 3.4 13.2 ± 4.5 12.6 ± 4.0 -0.65 (-
1.79, 0.49) 
0.48 -0.58 (-
1.68, 0.53) 
0.44 
        
Exercise Tolerance        
Time-to-exhaustion (s) 478 ± 80 550 ± 143 539 ± 108 -72.25 (-
169.49, 
24.99) 
0.62 -10.75 (-
97.30, 
75.80) 
0.10 
Values are presented as the mean ± SD. * = significantly different from CON (P<0.05). 95% 
CI = 95% confidence interval. 
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